Eton Pharmaceuticals (NASDAQ:ETON) Price Target Raised to $37.00 at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective lifted by analysts at HC Wainwright from $35.00 to $37.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 117.78% from the stock’s current price.

Other analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research raised shares of Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Wall Street Zen downgraded shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $30.33.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock opened at $16.99 on Monday. The firm has a market cap of $455.67 million, a PE ratio of -67.96 and a beta of 1.19. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The business has a 50-day moving average price of $16.17 and a 200 day moving average price of $17.23.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Opaleye Management Inc. increased its holdings in shares of Eton Pharmaceuticals by 0.3% in the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after purchasing an additional 7,930 shares during the last quarter. EcoR1 Capital LLC raised its holdings in shares of Eton Pharmaceuticals by 2.0% during the 2nd quarter. EcoR1 Capital LLC now owns 2,030,544 shares of the company’s stock worth $28,935,000 after acquiring an additional 40,756 shares during the period. Vanguard Group Inc. raised its holdings in shares of Eton Pharmaceuticals by 2.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock worth $29,208,000 after acquiring an additional 31,942 shares during the period. Geode Capital Management LLC boosted its position in shares of Eton Pharmaceuticals by 98.8% during the 2nd quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock valued at $8,450,000 after acquiring an additional 294,617 shares during the last quarter. Finally, State Street Corp grew its holdings in shares of Eton Pharmaceuticals by 14.5% in the fourth quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after purchasing an additional 63,480 shares during the period. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.